Edwards Lifesciences EW · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500
104.71
+2.52%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Edwards Lifesciences
From its filings with the US Securities and Exchange Commission
Edwards Lifesciences is based in Irvine, California and is incorporated in Delaware. Its shares trade on NYSE under the ticker EW. It is a member of the S&P 500. The SEC classifies its business as orthopedic, prosthetic & surgical appliances & supplies. In the fiscal year to 31 December 2025, it reported revenue of $6.07bn and net income of $1.07bn. At that date it held total assets of $13.70bn and shareholders' equity of $10.34bn. By business, Transcatheter Aortic Valve Replacement brought in 74.0% of revenue, followed by Surgical Structural Heart at 17.0% and Transcatheter Mitral and Tricuspid Therapies at 9.1%.
Edwards Lifesciences Corporation is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence, and meaningful partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Edwards Lifesciences has been a leader in our field for over six decades. Since our founder, Miles “Lowell” Edwards, first dreamed of using engineering to address diseases of the human heart, we have steadily built a company on the premise of imagining, building, and realizing a better future for patients.
Our innovative work encompasses both surgical and transcatheter therapies. In addition, our unique portfolio of repair and replacement technologies for aortic, mitral, tricuspid and pulmonic heart valves provides a broad set of treatment options to serve the many diverse and complex patients in need. Edwards remains committed to its strategy of transformative product innovation, high-quality, expansive clinical evidence to support approvals and adoption, as well as comprehensive support to ensure excellent real-world patient outcomes.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 27 Mar 2000
- Employees
- 16,000
- Website
- edwards.com ↗
- Head office
- ONE EDWARDS WAY, IRVINE, CA, 92614
- Incorporated in
- DE
- Classification
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Nicholas ValerianiIndependent Chairman of the Board$496,464
- Mr. Bernard ZovighianChief Executive Officer, Director, since 2016$14.6m
- Mr. Scott UllemChief Financial Officer, Corporate Vice President$5.3m
- Mr. Wayne MarkowitzSenior Vice President - Surgical Structural Heart, General Manager
- Mr. Donald BoboCorporate Vice President - Strategy and Corporate Development$3.7m
- Ms. Annette BrulsCorporate Vice President - EMEACLA (Europe, Middle East, Africa, Canada and Latin America)
- Mr. Daveen ChopraCorporate Vice President - Transcatheter Mitral and Tricuspid Therapies$3.7m
- Mr. Daniel LippisCorporate Vice President - Transcatheter Aortic Valve Replacement
- Mr. Larry WoodCorporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart$4.6m
- Ms. Leslie DavisIndependent Director$344,950
- Dr. David FeinbergIndependent Director$291,444
- Mr. Kieran GallahueIndependent Director$349,955
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 61
- Environment
- 61
- Social
- 68
- Governance
- 53
- Direct emissions (scope 1)
- 15,682 t
- Energy emissions (scope 2)
- 31,871 t
- Value chain emissions (scope 3)
- 571,975 t
- Women in the workforce
- 59%
- Carbon reduction policy
- No
- Human rights policy
- Yes
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.